|Mr. Paul Kang||CEO & Director||N/A||N/A||1962|
|Ms. Jiyoung Hwang||CFO & Director||N/A||N/A||1977|
|Mr. Joshua Miller||Chief Accounting Officer||N/A||N/A||1976|
|Mr. Bart Anderson||Senior Director of R&D||N/A||N/A||N/A|
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 7; Compensation: 10.